Role of interleukin-23 circulating levels increase in resected XXXX before and after chemotherapy: preliminary data and future perspectives.

@entity1 @entity32 @entity5 @entity14 @entity4452
Expression of @entity4452 , a heterodimeric cytokine involved in the induction of Th17 cells, is increased in @entity1 @entity5 . Although the endogenous @entity4452 expression has been reported to promote @entity5 development and growth, the studies using local and systemic administration of @entity4452 have shown that its application at the excessive amount induces antitumor immune responses. @entity4452 is, today, considered the key driver of intestinal @entity32 and its role in inflammatory responses is tissue-specific. The aim of this study was to investigate the role of circulating levels of @entity4452 in @entity1 with resected @entity14 ( @entity14 ) before and after chemotherapy, respect to healthy controls. Twenty-five @entity1 were enrolled between June 2007 and January 2009, and followed through 2010. All @entity1 underwent chemotherapy, mostly FOLFOX4. Twenty-sex and age-matched healthy donors were recruited as controls. @entity4452 serum concentrations, measured by a quantitative enzyme immunoassay technique, were significantly higher in @entity1 with resected @entity14 (26.02        28.63   pg/ml versus 7.1        6.4   pg/ml, P   <   0.001) and after chemotherapy respect to controls (21.74        23.82   pg/ml versus 7.17        6.43   pg/ml, P   <   0.001). An increase was documented also before chemotherapy (26.02        28.63   pg/ml versus 21.74        23.82   pg/ml, P   =   0.7) but not statistically significant. This work investigated, for the first time, the role of @entity4452 in @entity14 resection and chemotherapy, showing no correlation with the severity of disease, @entity5 removal, and chemotherapeutic treatment. However, other works are needed to better clarify if @entity4452 could be considered a key-molecule in @entity1 @entity14 and a target for @entity5 treatment.
